Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Gastro Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Gastro Other
    Everolimus Is an Effective Treatment Option for Patients With Pancreatic Neuroendocrine Tumours: Presented at ESMO-GI - (DGDispatch)
    Proton Pump Inhibitors May Increase Risk for Clostridium difficile Outbreaks: Presented at ICC - (DGDispatch)
    Efficacy of Vaccination Against Traveller's Diarrhoea: Presented at ESPID - (DGDispatch)
    CT Colonography May Help High-Risk Patients Adhere to Follow-up Screening - (DGNews)
    Sevelamer Carbonate Approved in EU for Patients With Chronic Kidney Disease - (DGNews)

    News archive

     Recent webcasts/CME - Gastro Other
    • Biologics in Crohn's Disease: Treating Early, Treating Long-Term
    • Long-Term Sustainability Using Biologics in Crohn's Disease
    • Recent Updates in Crohn's Disease: Optimising Remission, Healing, and Quality of Life
    • Advances in the Management of Postoperative Ileus: Reducing the Clinical and Economic Burden
      Irritable Bowel Syndrome with Constipation (IBS-C): Improving Patient Care Assessment and Management

      Webcasts/CME archive

       Recent cases - Gastro Other
        An Unexpected Cause of Iron Deficiency Detected by Capsule Endoscopy
        Acute Abdominal Pain in a Patient Receiving Enoxaparin
        Splenic Rupture Following Colonoscopy, A Rare Complication
        Accurate Localization of Life Threatening Colonic Hemorrhage During Nuclear Medicine Bleeding Scan as an Aid to Selective Angiography
        Disabling Osteomalacia and Myopathy as the Only Presenting Features of Celiac Disease: A Case Report

        Cases archive
          




        my personal edition > gastro other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Porcine Whipworm Active Against Crohn's Disease: Presented at DDW

        By Charlene Laino

        NEW ORLEANS, LA -- May 20, 2004 -- The porcine whipworm Trichuris suis may be effective for the treatment of Crohn's disease, suggest the results of an open-label study.

        Joel V. Weinstock, MD, Professor of Gastroenterology-Hepatology, and Director, Center for Digestive Diseases, University of Iowa College of Medicine, Iowa City, Iowa, presented the findings here on May 18th at the Digestive Disease Week Annual Meeting.

        Worms "don't just sit around; they have beneficial effects," he added. Colonization with helminth, a parasitic worm, is associated with down-regulation of the immune response, and Crohn's disease appears to result from an inappropriate immune response to normal gut flora, Dr. Weinstock explained.

        "Crohn's disease, like many other disorders, is a disease of the 20th century," he said. "We're the only people in history who have lived without [intestinal] worms. So we wanted to see if giving worms could be therapeutic."

        To determine if use of T. suis – a genus of nematode worms comprising the whipworm – Dr. Weinstock and colleagues conducted a study of 29 patients with a score of 220-450 points on the 600-point Crohn's Disease Activity Index (CDAI) and had not responded to conventional treatments.

        All the patients were administered 2,500 T. suis ova, dissolved in a popular beverage, every 3 weeks, and were evaluated for 24-weeks, Dr. Weinstock said. The researchers used pig whipworm, which colonize in humans for a short period of time he said.

        By week 12, 62% of patients were in remission, defined as a CDAI of less than 150 points. Altogether, 76% of patients experienced a decrease in CDAI of more than 100 points or had a CDAI of less than 150 points.

        There were no side effects or complications due to the therapy, although 4 patients dropped out of the study when their symptoms flared up and another withdrew due to pregnancy, Dr. Weinstock said.

        Future research should include study of other helminths, which might be even more potent, he said, adding, "we might be able to isolate the compounds in worms that are responsible for the beneficial effect and use them to create new synthetic agents."


        [Presentation title: "Trial of helminth ova in active Crohn's disease." Abstract 580]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send